TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02548052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2981278 0.03%
Description: GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.03%. Approximately 200 microliters of the GSK2981278 0.03% ointment will be applied topically to the assigned test field once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2981278 0.1%
Description: GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.1%. Approximately 200 microliters of the GSK2981278 0.1% ointment will be applied topically to the assigned test field once daily.
Study: NCT02408406

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01555281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: In phase II, the recommended dose of nelfinavir will be administered orally twice daily (in the morning and in the evening) on d1-d21 every 28 days for a maximum of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg of lenalidomide (capsules) will be administered orally daily on d1-d21 every 28 days for a maximum of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg (for patients \<75 years) or 20 mg (for patients ≥75 years) of dexamethasone (tablets) will be administered orally once per day on d1, 8, 15 and 22 every 28 days for a maximum of 4 cycles
Study: NCT02905721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spectral cardiac CT scan
Description: Cardiac CT scan : acquisition using the spectral mode imaging in order to identify inflammatory areas of the myocardium on the iodine map imaging.
Study: NCT00756847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408),
Description: Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous injection dosed once every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Intravenous injection dosed once every three weeks
Study: NCT01131728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium & Pseudoephedrine HCl
Description: Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium & Pseudoephedrine HCl
Description: Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
Study: NCT04097561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab 10 mg/kg once every 2 weeks for 3 doses, and then once every 4 weeks for 5 doses, delivered via 1-hour intravenous (IV) infusion.
Study: NCT04357028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Measles-Mumps-Rubella Vaccine
Description: Measles mumps Rubella vaccine is a weak attenuated life vaccine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
Study: NCT02765529

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Study: NCT00578994

Intervention type: DEVICE
Intervention: Oxford® Meniscal Unicompartmental Knee System
Description: Oxford® Meniscal Unicompartmental Knee System is a medial, unicompartmental knee prosthesis containing three components: a femoral component, a tibial component, and a tibial meniscal bearing.
Study: NCT01518868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational contact lens
Description: Worn on a daily wear basis for one week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PureVision contact lens
Description: Worn on a daily wear basis for one week
Study: NCT01673802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT scan
Description: Gadoxetate (Eovist) enhanced dual energy CT
Study: NCT02672111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2038 q1w or q4w exposure to SL BPN/NX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2038 q1w or q4w new to BPN treatment
Study: NCT01048528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Description: The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Relaxation techniques include progressive muscle relaxation, guided imagery, autogenics, meditation, and deep breathing. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
Study: NCT00179023

Intervention type: DRUG
Group type: OTHER
Intervention: Trimethaphan
Description: Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 2-4 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1 hour

Intervention type: DRUG
Group type: OTHER
Intervention: Trimethaphan
Description: Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 2-4 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1 hour

Intervention type: DRUG
Group type: OTHER
Intervention: Trimethaphan
Description: Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 2-4 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1 hour

Intervention type: DRUG
Group type: OTHER
Intervention: Trimethaphan
Description: Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 30 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1-2 hours

Intervention type: DRUG
Group type: OTHER
Intervention: Pseudoephedrine
Description: 30mg tablet,VO. Single dose.
Study: NCT00611143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: atorvastatin 20 mg/d, started 3 days before surgery
Study: NCT05595304

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prosthetic refunctioning
Description: Active treatment followed by regular interventions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional prosthetic treatment
Description: new prosthesis
Study: NCT00384228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study: NCT00890955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: * Dose Level -1: 20mg/m2~* Dose Level 1: 25mg/m2~* Dose Level 2: 30mg/m2~* Dose Level 3: 35mg/m2~* Dose Level 4: 40mg/m2~Amrubicin will be given as a slow IV push or infusion over approximately 5 minutes once daily for 3 consecutive days starting on day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given at a fixed dose as 500mg/m2 IV infusion over 30-60 minutes on day 1 of each 21 day cycle (following amrubicin).
Study: NCT04396613

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure technique
Description: Randomized assignment to one of three known, effective closure techniques
Study: NCT02548052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2981278 0.8%
Description: GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.8%. Approximately 200 microliters of the GSK2981278 0.8% ointment will be applied topically to the assigned test field once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2981278 4%
Description: GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 4%. Approximately 200 microliters of the 4% ointment will be applied topically to the assigned test field once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: GSK2981278 vehicle will be supplied as a white to off-white ointment containing no drug substance. Approximately 200 microliters of the vehicle will be applied topically to the assigned test field once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate 0.1%
Description: Betamethasone valerate will be supplied as a cream. Approximately 200 microliters of the 0.1% betamethasone valerate cream will be applied topically to the assigned test field once daily.
Study: NCT02596542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water immersion
Description: Different temperatures of cold water immersion will be assessed
Study: NCT03435809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine insemination
Description: Obligatory use of a Pozzi forceps tenaculum during intrauterine insemination

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine insemination
Description: Obligatory use of a Pozzi forceps tenaculum during intrauterine insemination
Study: NCT04734171

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital social activity video intervention
Description: A 150 seconds video aimed at encouraging the use of a digital device (i.e. not in person contact) to meet with friends during the COVID-19 pandemic. Two friends meet via zoom instead of in person and share their experiencing supporting each other.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational sheet
Description: An informational sheet to learn about the COVID-19 outbreak (standard).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational sheet
Description: An informational sheet to learn about the COVID-19 outbreak (standard).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Informational sheet
Description: An informational sheet to learn about the COVID-19 outbreak (standard).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stigma awareness video intervention
Description: A video aimed at sensitizing participants to COVID-19 related stigma. A COVID-19 + individual share their experience.
Study: NCT02362100

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non operative
Description: non operative treatment
Study: NCT04396613

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure technique
Description: Randomized assignment to one of three known, effective closure techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure technique
Description: Randomized assignment to one of three known, effective closure techniques
Study: NCT02362100

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: locking plate surgical fixation
Study: NCT04120623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: Dapagliflozin 10 MG combined with Insulin Aspart infused by continuous subcutaneous insulin infusion ( CSII).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Insulin Aspart is infused through continuous subcutaneous insulin infusion ( CSII)
Study: NCT00100945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Study: NCT00308009

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Repair for prolapse, TVT procedure
Description: 1. TVT at the time of Vaginal Repair~2. TVT 3 months after Vaginal Repair
Study: NCT03998618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Across six weekly 50-minute sessions, patients in the Acceptance and Commitment Therapy condition will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' cancer experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to fatigue. Participants will receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education/Support
Description: Across six weekly 50-minute sessions, patients in the education/support condition will discuss their concerns, including symptoms and other cancer-related stressors, with a therapist providing psychological support. The therapist will direct patients to resources for practical and health information and contact information for psychosocial services. Sessions will include an orientation to the patient's medical center, education regarding common cancer-related symptoms and quality-of-life concerns, and an overview of resources for addressing these concerns. The therapist will also describe resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants will receive handouts on session topics and will be asked to review them as homework.
Study: NCT01713413

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxymizer
Description: Using first the Oxymizer and 24 h later the conventional nasal cannula.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional nasal cannula
Description: Using first the conventional nasal cannula and 24h later the Oxymizer
Study: NCT00167544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone 3 mg/kg/d divided q 12h IV/PO tapered over 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT03585244

Intervention type: OTHER
Intervention: weekly weight
Description: weekly weight data collection for six months
Study: NCT01904812

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire about quality of life and satisfaction
Study: NCT02388633

Intervention type: PROCEDURE
Intervention: Plasmapharesis
Description: Clinically-indicated LDL apheresis
Study: NCT00969033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008
Description: CS-1008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: irinotecan
Study: NCT01618838

Intervention type: RADIATION
Group type: OTHER
Intervention: CyberKnife radiosurgery
Description: Treatment Planning:~Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the Planning Treatment Volume (PTV) and critical normal structures. The homogeneous CT model shall be used. Number of paths and beams used for each patient will vary and will be determined by the selected individual treatment plan. To reduce overall treatment time and total monitor units, 150-200 non-zero beams are recommended. No more than 250 beams shall be employed. Tuning structures shall be employed to minimize conformality index (CI) and new conformality index (nCI), preferably yielding values less than 1.20 and 1.25, respectively.
Study: NCT02440958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified FOLFIRINOX regimen
Description: Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks
Study: NCT03705091

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: ASL and DWI MRI
Study: NCT04493398

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gracey curette.
Description: Root planed was performed with curettes (Gracey SAS, Hu-Friedy, Chicago, IL, USA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic scaler.
Description: Debridement was performed with an ultrasonic scaler (Piezon Master 400 Perio Slim Tip®; Electro Medical System, Nyon, Switzerland).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erythritol air-polishing.
Description: Treatment was performed with a low abrasive erythritol powder (Air-flow powder plus®, EMS, Nyon, Switzerland ) applied through a Perio-Flow hand piece connected to an airflow unit (Air-Flow Master®, EMS, Nyon, Switzerland).
Study: NCT03910153

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MSPrebiotic
Description: MSPrebiotic digestion resistant starch from potatoes (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the potato resistant starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MSPrebiotic
Description: MSPrebiotic digestion resistant starch from potatoes (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the potato resistant starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn starch (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the corn starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn starch (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the corn starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
Study: NCT02457572

Intervention type: PROCEDURE
Intervention: Valsalva maneuver
Description: Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration.

Intervention type: OTHER
Intervention: Fluid loading
Description: We record the cardiac index values before and after volume expansion with 6ml/kg of balanced crystalloid
Study: NCT02581280

Intervention type: OTHER
Intervention: Residual blood
Description: Residual blood samples(1\~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).

Intervention type: OTHER
Intervention: Residual blood
Description: Residual blood samples(1\~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
Study: NCT01976962

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body RT with MR-guided boost
Description: Patients will receive radiotherapy over 5 fractions delivered once per week over 29 days, with 7.25 Gy per fraction to the whole prostate and 8 Gy per fraction to the dominant intraprostatic lesion. There will be a minimum of 120 hours and maximum of 192 hours between fractions. The entire course of treatment should be completed within no less than 27 days and no longer than 30 days.
Study: NCT01632605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Coated tablets, 1mg and 2mg available. Daily oral single dose with trough levels of 4-8ng/mL. Total intake for 6 months.
Study: NCT00987974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: rosuvastatin 20 mg/day for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin 3 days
Description: atorvastatin 80 mg/day for 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin 7 days
Description: rosuvastatin 20 mg/day for 7 days
Study: NCT00662584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: transcranial magnetic stimulation (TMS) at .5 HZ for 20s
Study: NCT03767153

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venus Viva
Description: The Venus Viva™ fractional RF applicator has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.~Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Viva
Description: The Venus Viva™ fractional RF applicator has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.~Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.
Study: NCT00942578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg cycle 1 day 1, repeated every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Once daily days 1-14 of every 21
Study: NCT02177097

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: 4 x 10 ml blood samples.

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: 4 x 10 ml blood samples.

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: 4 x 10 ml blood samples.
Study: NCT04514029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40 mg started 2 weeks (+/-5 days) prior to apheresis through day +30

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intrathecal dexamethasone 8 mg on days -1, +6, +13 (+/-2 days)